Key result
MDG-1 prevents obesity and improves cardiometabolic profiles in mice via PPAR modulation.
Why the study?
The underlying mechanism by which MDG-1 improves hyperlipidemia is largely unknown.
Does MDG-1 improve dyslipidemia and obesity in male C57BL/6 mice fed a high-fat diet?
RCT
Randomly separated
Does MDG-1 improve dyslipidemia and obesity in male C57BL/6 mice fed a high-fat diet?
MDG-1 demonstrates potential as a hypolipidemic agent by preventing obesity and improving lipid and glucose metabolism in a mouse model, possibly via PPARα activation and PPARγ inhibition.
Animal data on MDG-1 pathways require validation before any clinical consideration; leaves open translation to human hyperlipidemia.
, has been shown to improve abnormal blood lipid levels and alleviate diabetes. However, the underlying mechanism on hyperlipidemia is largely unknown. In this study, male C57BL/6 mice were randomly separated into three groups, respectively: low-fat diet (Con), high-fat diet (HFD), and high-fat diet plus 5‰ MDG-1 (HFD + MDG-1). Body weight was measured and the serum lipid levels were analyzed. Using gene microarray, various core pathways, together with levels of gene expression within hepatocytes, were analyzed. RT-PCR was used to confirm the identity of the differentially expressed genes. MDG-1 could prevent obesity in HFD-induced mice and improve abnormal serum lipids. Besides, MDG-1 could regulate hyperlipidemia symptoms, specifically, and decrease fasting blood glucose, improve glucose tolerance, and ameliorate insulin resistance. According to results from gene microarray, most of the identified pathways were involved in the digestion and absorption of fat, biosynthesis, and catabolism of fatty acids as well as the secretion and biological synthesis of bile acids. Furthermore, MDG-1 may act upon peroxisome proliferator-activated receptors (PPAR) α and γ, activating PPARα whilst inhibiting PPARγ, thus having a potent hypolipidemic effect.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) conducted an RCT in Dyslipidemia. MDG-1 vs. High-fat diet (HFD) and low-fat diet (Con) was evaluated on Body weight and serum lipid levels. MDG-1 prevented obesity and improved abnormal serum lipids, fasting blood glucose, and insulin resistance in high-fat diet-induced mice, potentially by activating PPARα and inhibiting PPARγ.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: